H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Kadmon Holdings (NYSE: KDMN) today and set a price target of $25. The company’s shares closed on Friday at $3.40.
Fein wrote:
“We derive comfort from the ongoing Phase 2a study of KD025 in cGVHD (data presented at the 23rd European Hematology Association (EHA) 2018), where it showed comparable clinical efficacy (ORR of 65%-69%) to Ibrutinib (ORR 67%, approved by FDA for adults with cGVHD in a cleaner safety profile (less infectious complications vs. Ibrutinib). In the pivotal trial of Ibrutinib, AEs occurred in at least 20% of the patients (fatigue, bruising, diarrhea, hemorrhage, pneumonia etc.), and one patient experienced grade 3 atrial fibrillation.”
According to TipRanks.com, Fein is a 3-star analyst with an average return of 2.7% and a 45.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Kadmon Holdings with a $15.75 average price target.
See today’s analyst top recommended stocks >>
Based on Kadmon Holdings’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $21.51 million. In comparison, last year the company had a GAAP net loss of $22.31 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. Its products include Ribasphere RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine.
